Charles River Labs stock sets USD 11.45 EPS outlook after Investor Day

Published on 09/25/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On September 24, 2026, management outlined 5% to 7% organic revenue CAGR through 2030. Mizuho lifted its target from USD 264 to USD 295 on September 25.

Moderner CRO-Forschungscampus mit Glasfassade in Wilmington Massachusetts — Charles River Laboratories Forschungscampus in Wilmington Massachusetts, modernes Glaslaborgebäude, ISIN US1591881009, Außenansicht, Illustration mit AI erstellt.

Charles River Labs (ISIN US1591881009) was trading at USD 293.19 on the NYSE at 10:32 a.m. ET on September 25, 2026, down 0.42 percent from USD 294.44. The latest catalyst is the companys Investor Day, where management positioned 2026 earnings at the upper end of its guidance range.

Investor Day sets long term targets

Charles River expects 2026 non-GAAP earnings per share at the upper end of USD 11.15 to USD 11.45, while organic revenue growth is expected at the upper end of 0 percent to 1 percent, according to StockTitan in the company release dated September 24, 2026.

The same release sets a 5 percent to 7 percent organic revenue compound annual growth target through 2030. Charles River also expects more than USD 300 million in cumulative savings from 2027 through 2030, giving the long term plan a measurable efficiency component.

Analysts raise their targets

Mizuho raised its price target from USD 264 to USD 295 while keeping a Neutral rating, as Investing.com reported on September 25, 2026. The new target is USD 1.81 above the intraday price, a gap of 0.62 percent.

The fundamental backdrop is mixed but improving. In the second quarter of 2026, Charles River reported revenue of USD 1 billion and earnings per share of USD 3.02 against consensus of USD 2.74, according to Investing.com. Revenue exceeded the USD 976.13 million forecast by USD 23.87 million.

Stock trades below yearly high

Charles River Labs shares were USD 10.12 below the 52-week high of USD 303.31 and USD 147.87 above the 52-week low of USD 145.32 on September 25, 2026. The NYSE quote carried a volume of 110,040 shares at 10:32 a.m. ET, while market capitalization stood at USD 14,122,287,963.

The valuation debate now rests on whether the announced 2030 growth path can translate into sustained earnings expansion. The companys second-quarter EPS beat and the upper-end 2026 outlook support that case, while Mizuho kept its Neutral rating after lifting its target.